Mounjaro vs. Ozempic: two molecules for type 2 diabetes

Both drugs treat type 2 diabetes alongside diet and exercise, and both are injected once a week at any time of day.

How they work. Semaglutide copies GLP-1, a gut hormone that boosts insulin when glucose is high, lowers glucagon, slows digestion and reduces hunger. Tirzepatide does the same and also activates the GIP receptor, a second incretin pathway.

Who they cover. Mounjaro (Eli Lilly, 2022) is approved for adults and, since December 2025, for children 10 and older. Ozempic (Novo Nordisk, 2017) is adult-only. Both labels now include reducing heart attacks, strokes and cardiovascular deaths in adults with diabetes at high risk; Mounjaro gained that indication in 2026 on the strength of SURPASS-CVOT. Ozempic alone adds slower kidney decline in chronic kidney disease.

Doses. Mounjaro starts at 2.5 mg, moves to 5 mg after four weeks, then can climb in 2.5 mg steps to 15 mg for adults or 10 mg for children. Ozempic goes 0.25 mg, 0.5 mg, 1 mg, then 2 mg.

Forms. Mounjaro comes as single-dose pens, vials and a four-dose KwikPen. Ozempic comes as multi-dose pens, and the same molecule is also sold as the daily Ozempic pill.

This pair has direct trial evidence, which is uncommon in the category.

SURPASS-2 (NEJM, 2021) randomized 1,879 adults with type 2 diabetes on metformin to tirzepatide 5, 10 or 15 mg or to semaglutide 1 mg for 40 weeks. Mean HbA1c fell 2.01, 2.24 and 2.30 percentage points on tirzepatide, against 1.86 on semaglutide, and every tirzepatide dose was superior. Weight loss was greater on tirzepatide by 1.9, 3.6 and 5.5 kg across the three doses.

The comparator dose is the main caveat. SUSTAIN FORTE (Lancet Diabetes & Endocrinology, 2021) later showed Ozempic 2 mg lowering HbA1c by 2.2 points over 40 weeks. That trial did not include tirzepatide, so the gap at Ozempic's top dose is unmeasured.

Heart and kidney outcomes. Ozempic's heart indication rests on semaglutide outcome trials. FLOW (NEJM, 2024) showed a 24% lower risk of major kidney events with semaglutide 1 mg in people with diabetes and kidney disease. SURPASS-CVOT (NEJM, 2025) tested tirzepatide in 13,299 adults with diabetes and heart disease; it was noninferior to dulaglutide for heart attack, stroke and cardiovascular death (hazard ratio 0.92). That result is now on Mounjaro's label, revised in 2026, as an indication to reduce major cardiovascular events in high-risk adults with type 2 diabetes.

The gut effects overlap heavily. In SURPASS-2, the one trial that gave both drugs, nausea ran 17–22% on tirzepatide and 18% on semaglutide 1 mg. Diarrhea was 13–16% versus 12%, and vomiting 6–10% versus 8%.

Low blood sugar needs more attention in diabetes than in weight care, because many people also take insulin or a sulfonylurea. The Mounjaro label reports glucose below 54 mg/dL in 13.8% of people on 5 mg with a sulfonylurea, in a trial lasting up to 104 weeks. Both labels say insulin or sulfonylurea doses may need lowering.

People with diabetic retinopathy need monitoring for progression on either drug. Both labels also list pancreatitis, gallbladder disease, kidney injury from dehydration and aspiration risk under general anesthesia. Neither is used with a personal or family history of medullary thyroid carcinoma or MEN 2, a restriction that stems from thyroid tumors in rodent studies.

Mounjaro fits adults, or children 10 and older, whose A1C needs a larger drop. It also fits adults who want more weight loss alongside glucose control. It outperformed semaglutide 1 mg on both measures in SURPASS-2, and it now carries a heart-risk indication too.

Ozempic fits adults with type 2 diabetes and chronic kidney disease, since the kidney claim belongs to Ozempic alone in this pair. It also suits people who may want to move to a tablet later, since the same molecule comes as the Ozempic pill.

Other medicines matter. If you use insulin or a sulfonylurea, expect your prescriber to review those doses when you start either drug. If you use birth control pills, the Mounjaro label advises a backup plan (see the FAQ).

Neither fits anyone with medullary thyroid carcinoma or MEN 2 in their personal or family history, or anyone with severe gastroparesis. Neither is a weight-loss product. For weight, the same molecules are sold as Zepbound (tirzepatide) and Wegovy (semaglutide).

Insurance coverage often decides the choice. If cost blocks both, raise it with your prescriber openly rather than stretching doses.